Information Provided By:
Fly News Breaks for July 6, 2018
BDSI
Jul 6, 2018 | 11:02 EDT
H.C. Wainwright analyst Oren Livnat said weekly prescription data through June 29 shows Belbuca trends are accelerating and prescription volumes are making new highs, with Q2 Belbuca sales trending to approximately $10.4M, topping the $9.8M consensus forecast. Belbuca's implied annualized run-rate of nearly $48M at the half-way point of the year compares favorably to the 2018 consensus of about $41M, added Livnat, who keeps a Buy rating on BioDelivery Sciences shares.
News For BDSI From the Last 2 Days
There are no results for your query BDSI
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.